THE ROLE OF BIOSIMILAR DRUGS IN LOWERING HEALTHCARE COST

Abstract: U.S. Food and Drug Administration could develop a new authorization process for biosimilars. These biological medicines are very similar to standard medicines efficacy and productiveness, but are facricated by different companies. (FDA) aims to increase access to health care and lower prices through the Biologics Price Competition and Innovation Act of 2009 (BPCIA), validated by the Patient Protection and Affordable Care Act (ACA) of 2010, and raise standards of care. Many pharmaceutical companies have pushed to speed up the development and FDA assessment of new biosimilars in the past years since the ACA to encourage more accessible, more affordable biologic medicines for patients. The success of the ACA depends on how easily and affordably novel biopharmaceuticals can be obtained. These BPCIA objectives must be accomplished by removing significant impediments to using biosimilars. Managed care and specialty pharmacy professionals are especially positioned to advise initiatives to remove these impediments. It is anticipated that the USFDA will publish final rules establishing the criteria for so-called biosimilar pharmaceuticals' lower-cost approval pathways. Although less so than with small-molecule generics, prices are predicted to drop with the launch of biosimilars. Biosimilars are cheaper versions of biological medicines that have been clinically evaluated, proven effective, and safe. Here is an overview of what biosimilars mean for healthcare today and their progress to date, based on a stakeholder assessment of biosimilars and their claimed benefits.